Individualized dosing patterns in the treatment of older patients with gastrointestinal stromal tumors: Results of a registry-based observational national cohort study including 871 patients

This study examined age-related differences in tyrosine kinase inhibitor (TKI) dosing for patients with gastrointestinal stromal tumors (GIST) and found that older patients (≥70 years) experienced more adverse events leading to dose adjustments compared to younger patients (<70 years). Older patients also showed higher imatinib plasma concentrations within the first year of treatment. Despite these dose reductions, there was no significant difference in overall survival between patients with or without dose adjustments, suggesting that reducing TKI doses in older patients does not compromise their outcomes.